Register for our free email digests:
Catherine Longworth is a reporter covering commercial and R&D developments in the medtech industry. A graduate of St. George's, University of London, Catherine holds a BSc in Biomedical Science. Before joining Informa, she worked in the editorial team at Pharmaceutical Press, the publishing division of the Royal Pharmaceutical Society, where she wrote and edited for a number of pharmaceutical publications. After gaining experience in the world of scientific publishing, Catherine took the leap to study a postgraduate qualification in journalism. During the course, she carried out placements with local London newspapers, writing general news and building her portfolio by reporting on a wide range of current affairs such as the European migrant crisis, political protests and the London mayoral election. Catherine is passionate about human rights and is fascinated by the innovative nature of the medtech industry and the healthcare advances that have the greatest benefit to mankind. She lives in London and loves music, arts, travel, writing, reading and is always happy to receive recommendations for books or places to travel!
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Catherine Longworth
Molecular diagnostics company genedrive has signed a distribution agreement with Sysmex Corporation to distribute its CE-marked HepC (HCV) ID kit and Genedrive platform in the Europe, Middle East and Africa. The Japanese group is the first commercial partner for genedrive's hepatitis C test for decentralized resource-limited settings.
Jason Hannon, former president and COO of spinal device manufacturer NuVasive Inc., has officially assumed the role of CEO and director of Irish company Mainstay Medical. He replaces Peter Crosby, who announced he would step down from the business in September.
Recent studies completed by epigenetic biomarker company Oxford BioDynamics have shown the company's platform technology EpiSwitch can diagnose and stage breast cancer and Amyotrophic Lateral Sclerosis (ALS). The Oxford spinout is the developer of a blood-based platform test for detecting chromosome confirmation signatures (CCSs), which overcome any ethinicity issues.
Cancer diagnostics company MDxHealth is poised for more commercial growth in 2018 following a move to larger lab facilities in Nijmegen, the Netherlands. The move is part of the company's strategy to grow commercialization of its SelectMDx prostate cancer test in Europe and conduct additional R&D activities.
Medtech M&A deal making has resumed the pace of activity seen before the brief surge in the summer. 17 M&A deals were announced and recorded on the Medtech Insight M&A deal tracker, one more than the previous month but included a few billion dollar transactions.
Swiss giant Roche has launched the NAVIFY tumor board, its first clinical decision-support product. The new, cloud-based software tool is designed to support the workflow of oncology-care teams by aggregating relevant data from multiple sources into one digital dashboard.